Trade Organogenesis Holdings Inc. - ORGO CFD
Add to favourite- Summary
- Historical Data
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 3.21 |
Open | 3.17 |
1-Year Change | -23.24% |
Day's Range | 3.16 - 3.22 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jul 25, 2024 | 3.19 | 0.21 | 7.05% | 2.98 | 3.25 | 2.98 |
Jul 24, 2024 | 3.08 | 0.01 | 0.33% | 3.07 | 3.23 | 3.07 |
Jul 23, 2024 | 3.15 | 0.23 | 7.88% | 2.92 | 3.16 | 2.92 |
Jul 22, 2024 | 2.99 | 0.14 | 4.91% | 2.85 | 3.02 | 2.84 |
Jul 19, 2024 | 2.88 | 0.06 | 2.13% | 2.82 | 2.94 | 2.81 |
Jul 18, 2024 | 2.92 | -0.06 | -2.01% | 2.98 | 3.01 | 2.89 |
Jul 17, 2024 | 3.01 | 0.02 | 0.67% | 2.99 | 3.09 | 2.98 |
Jul 16, 2024 | 3.07 | 0.24 | 8.48% | 2.83 | 3.07 | 2.83 |
Jul 15, 2024 | 2.87 | -0.02 | -0.69% | 2.89 | 2.91 | 2.81 |
Jul 12, 2024 | 2.88 | -0.04 | -1.37% | 2.92 | 2.97 | 2.86 |
Jul 11, 2024 | 2.93 | 0.09 | 3.17% | 2.84 | 3.02 | 2.84 |
Jul 10, 2024 | 2.84 | 0.06 | 2.16% | 2.78 | 2.84 | 2.73 |
Jul 9, 2024 | 2.76 | 0.03 | 1.10% | 2.73 | 2.77 | 2.68 |
Jul 8, 2024 | 2.78 | 0.00 | 0.00% | 2.78 | 2.93 | 2.75 |
Jul 5, 2024 | 2.76 | 0.07 | 2.60% | 2.69 | 2.77 | 2.67 |
Jul 3, 2024 | 2.76 | 0.13 | 4.94% | 2.63 | 2.78 | 2.62 |
Jul 2, 2024 | 2.64 | 0.01 | 0.38% | 2.63 | 2.70 | 2.62 |
Jul 1, 2024 | 2.68 | -0.14 | -4.96% | 2.82 | 2.82 | 2.68 |
Jun 28, 2024 | 2.77 | 0.13 | 4.92% | 2.64 | 2.81 | 2.63 |
Jun 27, 2024 | 2.61 | 0.14 | 5.67% | 2.47 | 2.65 | 2.47 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Organogenesis Holdings Inc. Company profile
About Organogenesis Holdings Inc
Organogenesis Holdings Inc. is a regenerative medicine company, which is focused on the development, manufacture, and commercialization of solutions for the wound care and surgical and sports medicine markets. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.
Financial summary
BRIEF: For the nine months ended 30 September 2021,Organogenesis Holdings Inc revenues increased 47% to$339.5M. Net income totaled $43.2M vs. loss of $545K.Revenues reflect an increase in demand for the Company'sproducts and services due to favorable market conditions.Basic Earnings per Share excluding Extraordinary Itemsincreased from -$0.01 to $0.34.
Industry: | Biotechnology & Medical Research (NEC) |
85 Dan Rd
CANTON
MASSACHUSETTS 02021-2810
US
News
![](https://img.capital.com/imgs/articles/192x130x1/Risk-Management-in-Trading.png)
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ECB_0.png)
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024![](https://img.capital.com/imgs/articles/192x130x1/risk_2_1_optimized_450_1.png)
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024![](https://img.capital.com/imgs/articles/192x130x1/Stock-1-_1.png)
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ETF-1-_0.png)
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024![Lloyds share price forecast: An attractive dividend stock? Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/192x130x1/shutterstock_536730610_0.jpg)
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024![](https://img.capital.com/imgs/articles/192x130x1/RBNZ.png)
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com